Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGPU NASDAQ:LNSR NASDAQ:NYXH NYSE:RVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$7.08$6.62$1.03▼$32.10$76.60M3.43223,504 shs75,991 shsLNSRLENSAR$6.40$5.74$5.06▼$13.47$78.60M0.87119,120 shs130,550 shsNYXHNyxoah$1.72$2.39$1.26▼$8.59$66.67M1.61730,855 shs110,361 shsRVPRetractable Technologies$0.73$0.68$0.60▼$1.14$21.86M1.2269,783 shs9,591 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology0.00%-1.12%-13.34%+73.96%+707,999,900.00%LNSRLENSAR0.00%+13.27%+13.88%+5.61%-51.11%NYXHNyxoah0.00%+2.99%-40.28%-51.69%-77.66%RVPRetractable Technologies0.00%+4.67%+10.64%+6.90%+13.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$7.08$6.62$1.03▼$32.10$76.60M3.43223,504 shs75,991 shsLNSRLENSAR$6.40$5.74$5.06▼$13.47$78.60M0.87119,120 shs130,550 shsNYXHNyxoah$1.72$2.39$1.26▼$8.59$66.67M1.61730,855 shs110,361 shsRVPRetractable Technologies$0.73$0.68$0.60▼$1.14$21.86M1.2269,783 shs9,591 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology0.00%-1.12%-13.34%+73.96%+707,999,900.00%LNSRLENSAR0.00%+13.27%+13.88%+5.61%-51.11%NYXHNyxoah0.00%+2.99%-40.28%-51.69%-77.66%RVPRetractable Technologies0.00%+4.67%+10.64%+6.90%+13.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGPUPredictive Oncology 1.00SellN/AN/ALNSRLENSAR 2.33Hold$10.0056.25% UpsideNYXHNyxoah 2.25Hold$7.00306.98% UpsideRVPRetractable Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RVP, AGPU, LNSR, and NYXH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026NYXHNyxoah Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$5.00 ➝ $3.006/1/2026AGPUPredictive Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026NYXHNyxoah Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026NYXHNyxoah Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$9.00 ➝ $7.005/12/2026NYXHNyxoah Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $5.005/11/2026LNSRLENSAR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)5/11/2026NYXHNyxoah Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026AGPUPredictive Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/22/2026NYXHNyxoah Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026LNSRLENSAR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026NYXHNyxoah Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.00(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGPUPredictive Oncology$50.29K1,523.29N/AN/A$11.69 per share0.61LNSRLENSAR$58.44M1.34N/AN/A($2.18) per share-2.94NYXHNyxoah$11.33M5.88N/AN/A$1.43 per share1.20RVPRetractable Technologies$37.15M0.59$0.02 per share48.25$3.31 per share0.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGPUPredictive Oncology-$233.10M-$8.18N/AN/AN/A-470,383.31%-7,363.67%-626.32%N/ALNSRLENSAR-$34.28M-$0.58N/AN/AN/A50.94%-183.19%42.26%8/6/2026 (Estimated)NYXHNyxoah-$101.92M-$2.48N/AN/AN/A-543.21%-163.73%-80.24%8/5/2026 (Estimated)RVPRetractable Technologies-$7.01M-$0.21N/AN/AN/A-41.11%-17.15%-9.33%N/ALatest RVP, AGPU, LNSR, and NYXH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026AGPUPredictive OncologyN/A-$0.36N/A-$0.36N/A$0.04 million5/12/2026Q1 2026NYXHNyxoah-$0.54-$0.43+$0.11-$0.43$7.05 million$7.38 million5/8/2026Q1 2026LNSRLENSAR$0.1850$1.56+$1.3750N/A$13.40 million$13.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGPUPredictive OncologyN/AN/AN/AN/AN/ALNSRLENSARN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/ARVPRetractable TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGPUPredictive OncologyN/A8.898.89LNSRLENSARN/A2.381.08NYXHNyxoah0.530.990.88RVPRetractable Technologies0.018.575.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGPUPredictive Oncology9.04%LNSRLENSAR40.15%NYXHNyxoahN/ARVPRetractable Technologies7.58%Insider OwnershipCompanyInsider OwnershipAGPUPredictive Oncology1.21%LNSRLENSAR65.80%NYXHNyxoah17.11%RVPRetractable Technologies59.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGPUPredictive Oncology3010.82 million10.69 millionN/ALNSRLENSAR11012.28 million4.20 millionOptionableNYXHNyxoah11038.76 million32.13 millionNot OptionableRVPRetractable Technologies24029.94 million13.47 millionOptionableRVP, AGPU, LNSR, and NYXH HeadlinesRecent News About These CompaniesRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersJune 30, 2026 | businesswire.comRetractable Stock Slips Post Q1 Earnings, Sales Decline Y/YMay 21, 2026 | zacks.comRetractable Technologies, Inc. Results for the Period Ended March 31, 2026May 15, 2026 | businesswire.comRetractable Technologies Shareholders Reelect Class 2 DirectorsMay 13, 2026 | tipranks.comRetractable Technologies, Inc. Announces Workforce ReductionApril 9, 2026 | businesswire.comRetractable Technologies Analyst Ratings and Price Targets | AMEX:RVP | BenzingaApril 9, 2026 | benzinga.comRVP Stock Plunges Post Q4 Earnings Despite Revenue GrowthApril 1, 2026 | zacks.comRetractable Technologies Declares Preferred Dividend Amid Tariff PressuresMarch 27, 2026 | tipranks.comRetractable Technologies: Q4 Earnings SnapshotMarch 27, 2026 | houstonchronicle.comHRetractable Technologies, Inc. Reports Results for 2025March 27, 2026 | businesswire.comRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersMarch 27, 2026 | businesswire.comRVP Stock Rises Post Q3 Earnings Despite Tariff and Cost PressuresNovember 20, 2025 | zacks.comRetractable Technologies, Inc. Results for the Periods Ended September 30, 2025November 14, 2025 | businesswire.comRetractable Technologies, Inc. Receives Innovative Technology Designation from Vizient for EasyPoint Blood Collection Tube Holder with NeedleNovember 14, 2025 | businesswire.comRetractable Technologies (NYSE:RVP) CEO Thomas Shaw Purchases 15,000 SharesNovember 1, 2025 | insidertrades.comInsider Buying: Retractable Technologies (NYSE:RVP) CEO Acquires 35,000 Shares of StockOctober 30, 2025 | insidertrades.comInsider Buying: Retractable Technologies (NYSE:RVP) CEO Buys 34,506 Shares of StockOctober 29, 2025 | insidertrades.comRetractable Technologies (NYSE:RVP) CEO Acquires $13,209.72 in StockOctober 16, 2025 | insidertrades.comRetractable Technologies (NYSE:RVP) CEO Thomas Shaw Buys 30,000 SharesOctober 10, 2025 | insidertrades.comRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersSeptember 30, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRVP, AGPU, LNSR, and NYXH Company DescriptionsPredictive Oncology NASDAQ:AGPU$7.08 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$7.15 +0.07 (+0.99%) As of 07/2/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.LENSAR NASDAQ:LNSR$6.40 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$6.43 +0.03 (+0.47%) As of 07/2/2026 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Nyxoah NASDAQ:NYXH$1.72 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.72 0.00 (-0.29%) As of 07/2/2026 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.Retractable Technologies NYSE:RVP$0.73 0.00 (0.00%) Closing price 07/2/2026 03:59 PM EasternExtended Trading$0.73 0.00 (-0.15%) As of 07/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
